OBJECTIVE: To assess the longitudinal health-related quality of life (HRQL) of children receiving hematopoietic stem cell transplantation (HSCT). METHODS: Mothers (N = 160) of HSCT recipients aged 5-20 at six US transplant centers completed the Child Health Ratings Inventories (CHRIs), the Disease Impairment Inventory (DSII)-HSCT module, and the Short Form (SF)-36 at baseline, 3, 6, and 12 months. RESULTS: HRQL domain scores at baseline varied by recipient age and program site. Longitudinal data over the first year post-HSCT revealed lowest functioning at baseline and 3 months, with largest improvement in functioning between the 3 and 6-months assessments and continued improvement from 6 to 12 months. Recipients of unrelated donor transplants had steepest declines in functioning at 3 months and great HSCT-specific issues at 3 and 6 months. Among children who survived the first year, functioning at 12 months was similar across transplant types and surpassed baseline scores. Children who did not survive the first year exhibited deterioration in HRQL in the months before death and trajectories were strikingly different than for survivors. CONCLUSIONS: This study offers the first glimpse of the 12-month trajectory of HRQL following pediatric HSCT from mothers' perspectives. This study also highlights the importance of and approaches to addressing missing data in longitudinal research.
OBJECTIVE: To assess the longitudinal health-related quality of life (HRQL) of children receiving hematopoietic stem cell transplantation (HSCT). METHODS: Mothers (N = 160) of HSCT recipients aged 5-20 at six US transplant centers completed the Child Health Ratings Inventories (CHRIs), the Disease Impairment Inventory (DSII)-HSCT module, and the Short Form (SF)-36 at baseline, 3, 6, and 12 months. RESULTS: HRQL domain scores at baseline varied by recipient age and program site. Longitudinal data over the first year post-HSCT revealed lowest functioning at baseline and 3 months, with largest improvement in functioning between the 3 and 6-months assessments and continued improvement from 6 to 12 months. Recipients of unrelated donor transplants had steepest declines in functioning at 3 months and great HSCT-specific issues at 3 and 6 months. Among children who survived the first year, functioning at 12 months was similar across transplant types and surpassed baseline scores. Children who did not survive the first year exhibited deterioration in HRQL in the months before death and trajectories were strikingly different than for survivors. CONCLUSIONS: This study offers the first glimpse of the 12-month trajectory of HRQL following pediatric HSCT from mothers' perspectives. This study also highlights the importance of and approaches to addressing missing data in longitudinal research.
Authors: Grace Chang; Sara J Ratichek; Christopher Recklitis; Karen Syrjala; Sunita K Patel; Lynnette Harris; Angie Mae Rodday; Hocine Tighiouart; Susan K Parsons Journal: Pediatr Blood Cancer Date: 2011-05-25 Impact factor: 3.167
Authors: Angie Mae Rodday; Robert J Graham; Ruth Ann Weidner; Norma Terrin; Laurel K Leslie; Susan K Parsons Journal: J Pediatr Health Care Date: 2017-06-16 Impact factor: 1.812
Authors: Brian W Pennarola; Angie Mae Rodday; Deborah K Mayer; Sara J Ratichek; Stella M Davies; Karen L Syrjala; Sunita Patel; Kristin Bingen; Mary Jo Kupst; Lisa Schwartz; Eva C Guinan; Judith H Hibbard; Susan K Parsons Journal: Med Care Res Rev Date: 2011-12-26 Impact factor: 3.929
Authors: Deborah K Mayer; S Ratichek; H Berhe; S Stewart; F McTavish; D Gustafson; S K Parsons Journal: J Cancer Surviv Date: 2009-12-06 Impact factor: 4.442
Authors: C M Jantien Vrijmoet-Wiersma; Annemarie M Kolk; Martha A Grootenhuis; Emmelien M Spek; Jeanine M M van Klink; R Maarten Egeler; Robbert G M Bredius; Hendrik M Koopman Journal: Support Care Cancer Date: 2008-12-03 Impact factor: 3.603